Woman With Alzheimer's Regains Speech After Mushroom Dose

After a decade of Alzheimer's disease left her nearly silent and dependent on full-time care, an elderly woman spontaneously began sharing memories and stories following a therapeutic dose of psilocybin mushrooms.

The Japanese American woman had spent five years in severe decline. She could barely speak, needed help with all daily activities, and had lost control of basic functions like walking independently.

Researchers in Brazil gave her two carefully measured doses of psilocybin-containing mushrooms one month apart. The first was 5 grams, followed by a 3-gram dose.

About 19 hours after the first treatment, something remarkable happened. The woman began talking on her own, sharing memories from her life in conversations that lasted several hours.

Over the following weeks, she regained abilities her family thought were gone forever. She walked without assistance, dressed herself, and held conversations while maintaining eye contact and smiling. Her urinary continence returned, a significant quality of life improvement.

The second dose brought even more progress. Her speech became more expressive, she showed humor in conversations, and her walking became steadier and more confident.

The changes lasted at least a month, according to the case report published in Frontiers in Neuroscience. Beyond initial sweating and extended sleep after the first dose, she experienced no serious side effects.

Why This Inspires

This single case cannot prove that psilocybin treats Alzheimer's disease. The study had no control group, no brain scans, and the diagnosis wasn't confirmed with modern biomarkers. Natural fluctuations in the woman's condition could explain some improvements.

Yet the possibility that a substance could temporarily reactivate neural pathways in advanced dementia opens new questions worth exploring. Dr. Marc Siegel of Fox News noted that while he remains cautious, he's "not surprised to see that psilocybin could temporarily overcome or alter the gummed-up circuitry" of Alzheimer's disease.

The Alzheimer's Association emphasizes that much larger controlled trials with brain imaging and cognitive assessments are needed before any conclusions can be drawn. Anyone considering treatments beyond approved medications should consult their healthcare provider about potential interactions and safety.

Several states including Oregon and Colorado have expanded legal access to psilocybin therapy in recent years, though it remains federally illegal. President Trump recently signed an executive order directing the FDA to expedite reviews of psychedelics designated as breakthrough therapies.

The research continues, driven by stories like this that remind us how much we still have to learn about the human brain.